BR112021019799A2 - Derivados contendo anéis de piridina como inibidores de malt1 - Google Patents

Derivados contendo anéis de piridina como inibidores de malt1

Info

Publication number
BR112021019799A2
BR112021019799A2 BR112021019799A BR112021019799A BR112021019799A2 BR 112021019799 A2 BR112021019799 A2 BR 112021019799A2 BR 112021019799 A BR112021019799 A BR 112021019799A BR 112021019799 A BR112021019799 A BR 112021019799A BR 112021019799 A2 BR112021019799 A2 BR 112021019799A2
Authority
BR
Brazil
Prior art keywords
derivatives containing
containing pyridine
pyridine rings
malt1 inhibitors
malt1
Prior art date
Application number
BR112021019799A
Other languages
English (en)
Inventor
Berthold Wroblowski
Jean-Claude Berthelot Didier
Stanislas M Diels Gaston
Wilhelmus John F Thuring Johannes
Tianbao Lu
Tongfei Wu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112021019799A2 publication Critical patent/BR112021019799A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Cosmetics (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

derivados contendo anéis de piridina como inibidores de malt1. são divulgados compostos, composições e métodos para tratamento de doenças, síndromes, condições e disfunções que são afetadas pela modulação de malt 1. tais compostos são representados pela fórmula (i) como se segue, em que as variáveis são definidas aqui.
BR112021019799A 2019-04-11 2020-04-10 Derivados contendo anéis de piridina como inibidores de malt1 BR112021019799A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962832608P 2019-04-11 2019-04-11
EP19178959 2019-06-07
PCT/EP2020/060307 WO2020208222A1 (en) 2019-04-11 2020-04-10 Pyridine rings containing derivatives as malt1 inhibitors

Publications (1)

Publication Number Publication Date
BR112021019799A2 true BR112021019799A2 (pt) 2021-12-07

Family

ID=70224393

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021019799A BR112021019799A2 (pt) 2019-04-11 2020-04-10 Derivados contendo anéis de piridina como inibidores de malt1

Country Status (12)

Country Link
US (1) US20220162187A1 (pt)
EP (1) EP3953345B1 (pt)
JP (1) JP2022528919A (pt)
KR (1) KR20210151880A (pt)
CN (1) CN113677674A (pt)
AU (1) AU2020272156A1 (pt)
BR (1) BR112021019799A2 (pt)
CA (1) CA3131856A1 (pt)
ES (1) ES2949871T3 (pt)
MA (1) MA55593A (pt)
MX (1) MX2021012417A (pt)
WO (1) WO2020208222A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116710089A (zh) * 2020-11-12 2023-09-05 莫诺泰罗斯疗法公司 治疗癌症的材料和方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2890695A2 (en) * 2012-08-29 2015-07-08 Respivert Limited Kinase inhibitors
SI3149001T1 (sl) 2014-05-28 2019-08-30 Novartis Ag Novi derivati pirazolo pirimidina in njihova uporaba kot inhimitorji malt1
AR106595A1 (es) * 2015-11-06 2018-01-31 Incyte Corp COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
BR112018009511A2 (pt) 2015-11-13 2018-11-06 Novartis Ag derivados de pirazolo pirimidina
CN107021963A (zh) * 2016-01-29 2017-08-08 北京诺诚健华医药科技有限公司 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用
JP2019522035A (ja) 2016-07-29 2019-08-08 ルピン・リミテッド Ｍａｌｔ１阻害剤としての置換チアゾロ−ピリジン化合物
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
WO2018165385A1 (en) * 2017-03-08 2018-09-13 Cornell University Inhibitors of malt1 and uses thereof
WO2018226150A1 (en) 2017-06-05 2018-12-13 Medivir Aktiebolag Pyrazolopyrimidine as malt-1 inhibitors
ES2966457T3 (es) 2018-06-18 2024-04-22 Janssen Pharmaceutica Nv Derivados de pirazol como inhibidores de MALT1
MX2020013699A (es) 2018-06-18 2021-05-12 Janssen Pharmaceutica Nv Derivados de pirazol como inhibidores de malt1.

Also Published As

Publication number Publication date
MA55593A (fr) 2022-02-16
AU2020272156A1 (en) 2021-10-14
JP2022528919A (ja) 2022-06-16
EP3953345B1 (en) 2023-04-05
EP3953345A1 (en) 2022-02-16
US20220162187A1 (en) 2022-05-26
KR20210151880A (ko) 2021-12-14
ES2949871T3 (es) 2023-10-03
WO2020208222A1 (en) 2020-10-15
CA3131856A1 (en) 2020-10-15
CN113677674A (zh) 2021-11-19
MX2021012417A (es) 2021-11-12

Similar Documents

Publication Publication Date Title
MX2022005827A (es) Derivados de pirazol como inhibidores de malt1.
MY196582A (en) PD-1/PD-L1 Inhibitors
BR112017019287A2 (pt) composto, composição farmaceuticamente aceitável, método de tratamento de câncer, processo para preparar o composto da fórmula i, método para tratar câncer, e kit
MX2017012730A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido) para el tratamiento de cancer.
BR112018070163A2 (pt) compostos de aminopurina substituída, composições e métodos de tratamento
UY38476A (es) Inhibidores de arg1 y/o arg2
BR112020008817B8 (pt) Compostos moduladores da via de estresse integrada
BR112017021167A2 (pt) composto, método de tratamento de câncer, e processo para preparar o composto de fórmula i
EA201890086A1 (ru) 1,4-замещенные производные пиперидина
MX2020006290A (es) Dinucleotidos ciclicos como agonistas de sting.
BR112019026080A8 (pt) Composições e métodos para modular o crescimento capilar
ECSP17020172A (es) Inhibidores de histona desmetilasa
MX2020013899A (es) Derivados de pirazol como inhibidores de malt1.
BR112021012829A2 (pt) Composições e métodos para modular o crescimento capilar
CO2021001219A2 (es) Benzimidazoles sustituidos como inhibidores de pad4
MX2020013699A (es) Derivados de pirazol como inhibidores de malt1.
PH12020552172A1 (en) Cyclic dinucleotides as sting agonists
PH12020500300A1 (en) Compositions and methods for modulating hair growth
WO2018183370A3 (en) Kdm4 inhibitors
BR112021019799A2 (pt) Derivados contendo anéis de piridina como inibidores de malt1
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
ZA202106519B (en) Caspase inhibitors and methods of use thereof
BR112022003584A2 (pt) Compostos de pirrolopirimidina inibidores de perk
BR112023023578A2 (pt) Composto, composição farmacêutica compreendendo o composto e método de tratamento de uma leucemia aguda
BR112021022960A2 (pt) Derivados de heterociclo fundidos como moduladores da montagem do capsídeo